Spots Global Cancer Trial Database for JAK-inhibition in Recurrent Classical Hodgkin Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: JAK-inhibition in Recurrent Classical Hodgkin Lymphoma
Official Title: A Phase II, Open-label, Prospective, Non-randomized, Multicenter Clinical Trial With the JAK-inhibitor Ruxolitinib in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Study ID: NCT02164500
Conditions
Interventions
Study Description
Brief Summary: The Purpose of this trial is: * to determine the overall response rate (ORR, complete response \[CR\] + partial response \[PR\]) in patients with relapsed or refractory HL * to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
1st Dept. of Medicine, Cologne University Hospital, Cologne, , Germany
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
